Margo Georgiadis is Co-Founder and CEO of Montai Therapeutics, a company pioneering at the intersection of machine learning, diverse untapped chemistry, and complex biology to discover transformative small molecule medicines for chronic disease. Starting with large unmet patient needs in inflammation and autoimmune diseases, Montai is advancing a pipeline of first in class once daily orals for validated biological pathways which have historically eluded small molecule developers – transcription factors and biologic replacements. Through partnerships, Montai also is developing therapies in oncology and antimicrobials. Margo also serves as a CEO-Partner at Flagship Pioneering, the bioplatform innovation company behind more than 100 scientific ventures in human health and sustainability.
Margo has dedicated her career to transforming products and services with data and technology to empower consumers to live better lives, and to deliver outsized growth and returns for investors. Prior to founding Montai, she held multiple senior leadership roles including President and CEO of Ancestry, and President of Americas and Vice President of Global Operations at Google. She is an experienced investor working at General Catalyst and Synetro Group in funding and scaling next generation technology and healthcare platforms.
Margo has received multiple awards for her business and community leadership including being named to Fortune’s “50 Most Powerful Women in Business,” and “Leaders50” most inspiring global leaders lists. She also was recognized with the Forbes “Excellence Award in Innovation,” Chicago Innovation’s “Visionary Award,” the Eastman Medal from the University of Rochester, Women Business Collaborative’s “Trailblazer in Gender Equity and Diversity,” and Executive of the Year in Utah. Margo serves on the Boards of several market leaders and innovators including McDonald’s, AppLovin, Handshake, Ro, Harbinger Health, and the Parker Institute for Cancer Immunotherapy.